www.fdanews.com/articles/188541-eu-gives-go-ahead-for-metastatic-melanoma-combo-therapy
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
EU Gives Go-Ahead for Metastatic Melanoma Combo Therapy
September 25, 2018
The EU approved Pierre Fabre’s Braftovi and Mektovi combination therapy for treating adults with unresectable or metastatic melanoma with a BRAFV600 mutation.
The approval was based on data from a Phase III trial, showing 14.9 months of median progression-free survival using the combination, compared to 7.3 months using vemurafenib monotherapy.
The combination therapy also showed a lower discontinuation rate due to suspected treatment-related adverse events — six percent — compared to vemurafenib’s 14 percent.